下一个

自动播放

Dr. Andrew Brohl at ASCO 2023: Abstract No. 9534

2 意见 • 07/17/23
分享
嵌入
administrator
administrator
订户
0

At ASCO 2023, Moffitt's Dr. Andrew Brohl discusses a phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.

显示更多
0 注释 sort 排序方式
脸书评论

下一个

自动播放